Methodological and Ethical Challenges for the Implementation of Complementary and Alternative Medicine-Related Clinical Trials: Review of Reviews

Nazila Javadi-Pashaki 1,2, Hamidreza Mehrabi 3, Iman Asdaghi-Jahromi 4, Seyedeh Mahjabin Taheri Otaghsara 5, Mohammad Javad Ghazanfari 6, Pooyan Ghorbani Vajargah 7, Amir Abbas Mollaei 8, Atefeh Falakdami 9, Poorya Takasi 7, Aghil Mollaei 8, Hatef Mashhadi 9, Samad Karkhah 7*

1. Social Determinants of Health Research Center (SDHRC), Guilan University of Medical Sciences, Rasht, Iran
2. Department of Nursing, Cardiovascular Diseases Research Center, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran
3. Student Research Committee, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran
4. Department of Anesthesiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
5. Student Research Committee, Nasibe School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran
6. Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Kashan University of Medical Sciences, Kashan, Iran
7. Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran
8. Department of Biostatistics, School of Health, Mazandaran University of Medical Sciences, Sari, Iran
9. Department of Geriatrics, School of Nursing and Midwifery, Kashan University of Medical Sciences, Kashan, Iran

Article Type: Review Article

Article History:
Received: 24 Jan 2022
Revised: 5 Sep 2022
Accepted: 10 Sep 2022
Published: 10 Jun 2022

*Correspondence:
Samad Karkhah
Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran
samad.karkhah@gums.ac.ir

Abstract

Background and Objectives: The implementation of complementary and alternative medicine (CAM) has increased in recent decades. Due to the positive effects of CAM interventions, 5 to 74.8% of people use these treatments worldwide. However, implementing CAM-related clinical trials is associated with challenging issues. Failure to address these challenges can lead to poor quality of studies, publication of non-scientific findings, and ultimately disregard for human rights and ethics. This review aims to comprehensively review the literature focusing on methodological and ethical challenges for implementing CAM-related clinical trials.

Material and Methods: This review of reviews was conducted via international databases, including PubMed/MEDLINE, Web of Science, and Scopus using keywords extracted from medical subject headings such as “Methods”, “Methodological Study”, “Methodological Studies”, “Ethics”, “Complementary Therapies”, “Complementary Medicine”, “Alternative Medicine”, “Clinical Trial”, and “review” from the earliest to May 1, 2022.

Results: In general, challenging issues for the implementation of CAM-related clinical trials can be divided into two categories: 1) methodological and 2) ethical. Methodological challenges included: Risk of bias, Lack of knowledge of researchers, and Blinding. On the other hand, ethical challenges in clinical trial studies are divided into two categories: patients' rights and placebo use.

Conclusion: Overall, the present study emphasizes the need for special attention to the quality of CAM-related clinical trials. Also, this study can pioneer the introduction of critical challenging issues in CAM-related clinical trials and provide appropriate suggestions for researchers to solve these issues in future studies.

Keywords: Methods [MeSH]; Complementary Therapies [MeSH]; Ethics [MeSH]; Clinical Trial [MeSH]
Methodological and Ethical Challenges for CAM-Related Clinical Trials  

Javadi-Pashaki N. et al.

**Highlights**
- Challenging issues for implementing complementary and alternative medicine (CAM)-related clinical trials can be divided into 1) methodological and 2) ethical.
- This study can pioneer the introduction of critical challenging issues in CAM-related clinical trials and provide appropriate suggestions for researchers to solve these issues in future studies.

**Introduction**

Implementation of Complementary and Alternative Medicine (CAM) has increased in recent decades (1-7). CAM consists of two components, including 1) complementary medicine and 2) alternative medicine. "Complementary medicine" is defined as non-mainstream practices that are not part of standard medical care but are used in conjunction with conventional medical methods. On the other hand, "alternative medicine" includes non-mainstream practices that are used instead of standard medical care (8-10). In general, CAM interventions can be divided into four main groups, including 1) mind-body-spirit therapies (such as imagery, yoga, and music therapy), 2) manipulative and body-based therapies (massage, tai chi, and relaxation therapies), 3) natural products (aromatherapy, and herbal medicines), and 4) energy therapies (light therapy, reflexology, acupressure) (11-14). Due to the positive effects of CAM interventions, 5 to 74.8% of people use these treatments worldwide (15-19). Nearly half of patients in the USA use CAM therapies to treat medical conditions and improve well-being (1). CAM is widely used to improve disease-related outcomes and patients' quality of life (20-25). Complaints of chronic diseases, physical disabilities, and mental stress play an essential role in the implementation of these treatments (15, 26, 27). However, the implementation of CAM-related clinical trials is associated with critical challenging issues (28, 29). Failure to address challenging issues can lead to poor quality of studies, publication of non-scientific findings, and ultimately disregard for human rights and ethics. Therefore, these challenging issues can be divided into two categories: 1) methodological and 2) ethical (30).

In relation to methodological challenges, one of the critical issues in clinical trial studies is the existence of biases. There are different types of biases in Randomized Controlled Trials (RCTs) (31). One of the most common is selection and implementation bias, and the best way to minimize selection bias is randomization, which means randomly assigning participants to study groups. Blinding can minimize implementation bias and produce more reliable results (32). Also, blinding the adverse effects of researchers 'and participants' awareness of the intended intervention reduces the results. However, there are criticisms of blindness (33-35). Ethical challenges have always been discussed, including issues such as using placebos, guaranteeing the rights and interests of participants, and attention to treatments' effectiveness or side effects (36).

It is evident that in the implementation of RCT studies, it is necessary to pay attention to ethical and methodological challenges, and since the results of RCT studies play an important role in therapeutic decisions and are presented as part of the body of knowledge; It is essential to observe the considerations that pay attention to the quality of studies. Dissemination of scientific and reliable findings can play an essential role in improving the quality of clinical care and complying with ethical principles, given the importance of ethical and methodological issues in the implementation of CAM-related clinical trials and the role of these issues in the publication of scientific and reliable findings, this review of reviews aimed to summarize the evidence regarding the methodological and ethical challenges for the implementation of CAM-related clinical trials.

**Materials and Methods**

This review of reviews was conducted via international databases, including PubMed/MEDLINE, Web of Science, and Scopus using keywords extracted from medical subject headings such as “Methods”, “Methodological...
Methodological and Ethical Challenges for CAM-Related Clinical Trials

Javadi-Pashaki N. et al.

Study”, “Methodological Studies”, “Ethics”, “Complementary Therapies”, “Complementary Medicine”, “Alternative Medicine”, “Clinical Trial”, and “review” from the earliest to May 1, 2022. For example, the search strategy was in PubMed/MEDLINE database including (“Methods”) OR (“Methodological Study”) OR (“Methodological Studies”) AND (“Ethics”) OR (“Bioethical Issues”) OR (“Morals”) OR (“Ethical Issues”) AND (“Complementary Therapies”) OR (“Complementary Medicine”) OR (“Alternative Medicine”) OR (“Alternative Therapies”) AND (“Clinical Trial”) OR (“Review”). Keywords were combined via Boolean operators (AND/OR). English-language published reviews related to the purpose of the present review were included. The search was performed by two authors independently. This review does not include gray literature such as expert opinions, conference presentations, dissertations, research and committee reports, and ongoing research. Gray literature includes articles produced in print and electronic formats but not evaluated by a commercial publisher (37). Lists of references from eligible studies were assessed manually to achieve maximum search comprehensiveness. Data management were conducted using the EndNote X8 software. A total of 974 articles were obtained initially using database searches. After removing the duplicates, two researchers independently evaluated the title, abstract, and full text of the articles based on inclusion/exclusion criteria. Finally, full texts of selected articles were reviewed, and six studies were included in this review (Figure 1).

![Figure 1. Flow diagram of the study selection process](image-url)
Results

The basic characteristics of the included studies in this review are presented in Table 1.

Methodological and ethical challenges for the implementation of CAM-related clinical trials

Overall, challenging issues for the implementation of CAM-related clinical trials can be divided into two categories: 1) methodological and 2) ethical.

1. Methodological

1.1. Risk of bias

Although the best and most accurate clinical trials to measure causal relationships, RCTs are always prone to various errors. Hence, one type of error in RCTs is called bias. This type of error is generally defined as any systematic error in the design, implementation, data collection, analysis, and interpretation of data that can distort the validity of the findings and conclusions. Bias can lead to underestimation or overestimation of the effects of RCT interventions. Based on a systematic review, half of the RCT studies on CAM implementation in hemodialysis patients had low bias (38).

1.2. Lack of knowledge of researchers

Some researcher-related challenging issues include lack of knowledge of researchers in the implementation of RCTs, lack of proper communication between the researcher and the statistical expert for randomization and sampling, weakness of researchers in correct randomization, non-use of blinding, failure to the management of sample erosion and report all relevant variables, small sample size, incomplete information regarding the validity and reliability of data collection tools, failure to consult with statisticians during the study, which require special attention by policy-makers in research fields and universities (38, 39).

1.3. Blinding or not?

In retrospect, the call for new methodologies appears to have been a reaction against the perceived dominance of the Randomized Controlled Trial (RCT). This reaction stemmed first from misconceptions regarding the nature of the RCT and second from a desire to ask what were thought to be new questions about medicine, the answers that cannot be determined by an RCT. Concerning the first point, it is interesting how often CAM practitioners and other commentators use the terms RCT and double-blind trial interchangeably (40).

This is an excellent example of how certain incidental or additional features of particular trials have been mistakenly perceived to be an integral part of the RCT. RCTs do not have to be double-blind. An RCT can still be conducted even if the therapy cannot be given in a double-blind fashion (38, 39).

In addition to double-blinding, several other features of clinical trial methodology have been said, by critics, to be a necessary component of any RCT. It has often been argued that RCTs should not be conducted because research on a CAM therapy should not involve a particular methodological technique and because such a technique is an inherent part of an RCT. Some examples of this kind of argument are given below. This is to show that rigorous RCTs can be conducted to solve real-world problems and which do not conform to the caricature of the "double-blind trial" (40).

One problem with focusing on paradigms, the problem with much of the early methodological debate was that, this approach is of limited use to prospective researchers. One of our primary roles at the Research Council for Complementary Medicine is to advise individuals who wish to get involved in research. An obvious first step would have been to refer an inquirer to the relevant methodological literature. Unfortunately, this is often of little benefit. Esoteric comparisons of "the reductionist causal" paradigm, said to characterize "orthodox" biomedical science, and the "integrative holistic" paradigm, said to be characteristic of CAM, were no doubt theoretically attractive, but they were of limited practical value (38, 39).
Table 1. Essential characteristics of the studies included in this review

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Title</th>
<th>Design</th>
<th>Number of included studies</th>
<th>Main Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huanhua et al., 2021</td>
<td>Challenges for ethics committees in biomedical research governance: illustrations from China and Australia</td>
<td>Narrative Review</td>
<td>45 Clinical trials</td>
<td>To maximize the benefits and minimize the risks to participants, the following aspects should be considered in the ethical review of clinical trials: (1) Calculate and minimize sample content in such a way as to prevent an overdose of treatment participants (2) Guaranteeing the rights and interests of the participants (3) Pay close attention to the occurrence of adverse events, including serious cases (4) An add-on design scheme can be adopted in which the experimental group and the control group can adopt standard treatment</td>
</tr>
<tr>
<td>Katz et al., 2021</td>
<td>Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations</td>
<td>Narrative Review</td>
<td>43 Clinical trials</td>
<td>Clinical trials have been criticized as double-blind.</td>
</tr>
<tr>
<td>Zhang et al., 2021</td>
<td>The Challenges of Ethical Review in Clinical Research of Traditional Chinese Medicine</td>
<td>Narrative Review</td>
<td>18 RCTs</td>
<td>Three recommendations for using a placebo in clinical trials: (1) the disease under investigation is limited and can be treated even without treatment (2) there is currently no specific treatment for the research disease, which means that new treatments should be considered (3) chronic illness and short-term absence of treatment will have no significant effect on the prognosis</td>
</tr>
<tr>
<td>Adib-Hajbaghery et al., 2019</td>
<td>Bias in clinical trials into the effects of complementary and alternative medicine therapies on hemodialysis patients</td>
<td>Narrative Review</td>
<td>114 RCTs</td>
<td>Half of the RCT studies related to CAM implementation in hemodialysis patients had low bias.</td>
</tr>
<tr>
<td>Mohammadi et al., 2014</td>
<td>Risk of Bias in Randomized Controlled Trials Published in Iranian Nursing and Midwifery Journals in 2010</td>
<td>Narrative Review</td>
<td>68 RCTs</td>
<td>The majority of studies had an unclear or high risk of bias. Random sequence generation in 22%, concealment allocation in 4.5%, blinding in 22%, incomplete outcome data in 35.3%, selective outcome reporting in 51.5%, and other bias in 36.7% of the studies was in low risk of bias.</td>
</tr>
<tr>
<td>Louis et al., 1983</td>
<td>Critical issues in the conduct and interpretation of clinical trials</td>
<td>Narrative Review</td>
<td>12 RCTs</td>
<td>Patients should be aware of the potential advantages and disadvantages of interventions and have the right to withdraw from the study at any stage of the study.</td>
</tr>
</tbody>
</table>
2. Ethical

2.1. Patient rights

Quality assurance to ensure the protection of patient rights is essential to research ethics in the implementation of CAM-related clinical trials. Also, one of the most important aspects of patient rights is informed consent, a primary concern in clinical trials. However, its proper implementation has been controversial in many cases. Patients should be aware of the potential advantages and disadvantages of interventions and have the right to withdraw from the study at any stage (41). It is suggested that researchers adhere to the Nuremberg Code and the Helsinki Declaration and institutional review boards, to resolve this challenging issue and promote ethical behaviors. Also, monitoring clinical trials and research ethics-related workshops is necessary to promote the ethical behaviors of researchers in clinical trials.

2.2. Use of placebo

In addition, the use of a placebo in RCTs is one of the main concerns in ethical studies in clinical trials. Especially when it is clear that effective treatment is available to prevent the progression of the disease, treating patients is not the only ethical placebo. However, there are three recommendations for the use of a placebo, including (1) the disease under investigation is limited and can be treated even without treatment, (2) there is currently no specific treatment for the research disease, which means that New treatment should be considered, and (3) chronic illness and short-term absence of treatment will have no significant effect on the prognosis (42).

However, to maximize the benefits and minimize the risks to participants, the following aspects should be considered in the ethical review of clinical trials: (1) Calculate and minimize sample content in such a way as to prevent overdose of treatment participants with poor efficacy or adverse reactions. (2) Guaranteeing the rights and interests of the participants; Ensuring the safety and reliability of pharmacological excipients or raw materials; in the placebo production process, the relevant materials must be in accordance with the relevant international standards to ensure the quality and safety of the placebo.

(3) Pay close attention to the occurrence of adverse events, including serious cases. (4) An add-on design scheme can be adopted in which the experimental and control groups can adopt standard treatment as the primary intervention to minimize the possibility of harm (43).

Conclusion

The present study emphasizes the need for special attention to the quality of CAM-related clinical trials. Also, this study can play an important role in introducing important challenging issues in clinical trials related to CAM and provide appropriate suggestions to researchers to solve these issues in future studies. While the importance of addressing barriers to conducting and applying research in CAM, it is recognized that, to date, addressing the barriers and challenges has been limited. Numerous barriers remain, requiring coordinated efforts and collaboration among various CAM stakeholders and across multiple sectors. Further research can contribute to the evidence base on how best to overcome these barriers to promote the conduct and application of research in CAM.

Funding

This research did not receive any specific grant from public, commercial, or not-for-profit funding agencies.

Declaration of Conflicting Interests

The Author(s) declare(s) that there is no conflict of interest

References


BMC complementary and alternative medicine. 2018;18(1):1-11. [DOI] [PMID] [PMCID] [Google Scholar]


Methodological and Ethical Challenges for CAM-Related Clinical Trials

Javadi-Pashaki N. et al.

2020;100666. [DOI] [PMID] [PMCID] [Google Scholar]


How to cite: